AbbVie (ABBV) Tax Provisions (2012 - 2026)

AbbVie has disclosed Tax Provisions across 15 years of filings, most recently posting $342.0 million for Q1 2026.

• In Q1 2026, Tax Provisions fell 8.06% year-over-year to $342.0 million; the TTM figure through Mar 2026 stood at $2.3 billion (up 501.72% YoY), while the FY2025 annual figure was $2.4 billion, up 514.74% from the prior year.
• Tax Provisions declined to $342.0 million in Q1 2026, from $853.0 million in the prior quarter.
• Over the last five years, Tax Provisions for ABBV reached as high as $853.0 million in Q4 2025 and fell as low as -$2.2 billion in Q4 2024.
• The 5-year median for Tax Provisions is $448.0 million (2022), against an average of $322.5 million.
• The widest YoY moves for Tax Provisions: up 202.33% in 2024, down 678.87% in 2024.
• A 5-year view of Tax Provisions shows it stood at $493.0 million in 2022, then retreated by 21.3% to $388.0 million in 2023, then slumped by 678.87% to -$2.2 billion in 2024, then jumped by 137.98% to $853.0 million in 2025, then plunged by 59.91% to $342.0 million in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered $342.0 million, $853.0 million, and $526.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.